Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies.
FAIL · Does not pass the screen
0.00 USD
At the last full screen 2026-06-14
Screened 2026-06-14 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Genocea Biosciences, Inc. holds its Distribution at $0.00. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-06-14
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$0.00
Valuation
N/A trailing · N/A forward price to earnings
Values screen
FAIL· score 70.0
Beta
36.91
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2,637,989.78%
Below 33%
Interest-bearing debt is 2,637,989.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
3,430,494.04%
Below 33%
Interest-bearing cash and securities are 3,430,494.0% of assets, above the one-third limit.
Fail
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-06-14 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GNCAQ trades on PNK. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-31Distribution · changed$0.00+0.0%Entry 5
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a moderate risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 900%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-07-31Markup$0.00+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a moderate risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 900%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-07-18Markup$0.00+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a moderate risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 900%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
2026-07-03Markup$0.00+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$0.00Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$0.00
+900.0%
·
$10,000
+900.0%
2 months
$0.00
+900.0%
·
$10,000
+900.0%
3 months
$0.00
+900.0%
·
$10,000
+900.0%
6 months
$0.00
+900.0%
·
$10,000
+900.0%
1 year
$0.00
+900.0%
·
$10,000
+900.0%
2 years
$0.00
+0.0%
·
$1,000
+0.0%
3 years
$0.00
-90.0%
·
$100
-90.0%
5 years
$2.59
-100.0%
·
$0
-100.0%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever GNCAQ does next, these words stay.
Genocea Biosciences, Inc. · GNCAQ · Distribution · $0.00
Recorded 2026-06-14 · before the outcome · scored mechanically